First wave of Certified Specialty Pharmacist credential recipients includes four from Diplomat
FLINT, Mich. — Four pharmacists from Diplomat are among the 49 across the country who have received certification from the Specialty Pharmacy Certification Board, Diplomat said Monday.
Diplomat said VP clinical services Gary Rice, clinical technology manager Michael Crowe, pharmacy manager Nicole Hubach and clinical manager Ryan Nolan had received the SPCB’s Certified Specialty Pharmacist endorsement. The SPCB announced on Nov. 11 the first 49 pharmacists to become CSPs. The tests for the credential were administered in October.
"I’m very excited to be one of the first Diplomat pharmacists to earn the CSP credential," Crowe said. "Diplomat has provided me with many opportunities to develop my expertise in specialty pharmacy. I encourage pharmacists and pharmacy students to explore the industry, as its growth will continue for the foreseeable future."
FDA approves J&J’s Olysio for hepatitis C
TITUSVILLE, N.J. — The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.
J&J subsidiary Janssen Therapeutics announced the approval of Olysio (simeprevir) for treatment of chronic hepatitis C in combination with the drug ribavirin and biotech drugs called pegylated interferons. The drug is meant for adults with HCV genotype 1 with compensated liver disease, including cirrhosis. The company said the drug may benefit patients who have the chronic form of the disease, including those who have not received treatment before or who have failed prior interferon-based therapy.
"Given the complexity of the condition, Olysio was studied in a number of different patient populations, including individuals who have relapsed or failed to respond to previous treatments," Olysio clinical trial investigator and Mount Sinai School of Medicine professor Douglas Dieterich said. "The FDA approval of Olysio is an important milestone for people living with chronic hepatitis C, as it means that patients have a new treatment option with the potential to cure this challenging disease."
FDA approves Bayer’s Nexavar for thyroid cancer
SILVER SPRING, Md. – The Food and Drug Administration has approved a drug made by Bayer HealthCare Pharmaceuticals for treating thyroid cancer, the agency said Friday.
The FDA announced the approval of Nexavar (sorafenib) to treat late-stage differentiated thyroid cancer. The drug was already approved for kidney and liver cancers. The drug works by limiting cancer cell growth and replication by inhibiting proteins within the cells.
"Differentiated thyroid cancer can be challenging to treat, especially when unresponsive to conventional therapies," FDA Office of Hematology and Oncology Products Richard Pazdur said. "Today’s approval demonstrates the FDA’s commitment to expediting the availability of treatment options for patients with difficult-to-treat diseases."